by DealForma Analysts | Mar 10, 2021 | Deal of the Month
Deal of the Month Biopharma Deal of the Month: Vir – GSK for VIR-2482 and mAbs for Influenza Top Biopharma Partnership by Upfront Cash and Equity February 2021 VIR and GSK Expanding VIR-2482 and mAb Development into Influenza Announced: Feb. 17, 2021 Total Deal...
by DealForma Analysts | Jun 20, 2019 | Analysis, Funding, M&A, Partnership Deals
Analysis | Funding | M&A | Partnership Deals Gene Therapy Deals, M&A, and Venture Funding Gene therapy deals, R&D partnerships, and acquisitions have been showing annual gains through 2018 and are on track to keep up the record in 2019. The recent...
by DealForma Analysts | Jun 13, 2019 | Analysis, M&A
Analysis | M&A Reverse Mergers in Biopharma Reverse mergers have been a relatively quick method for companies to gain a public listing as an alternative to IPOs. A private company looking to go public merges with a company that is already publicly traded and...
by DealForma Analysts | Jan 22, 2019 | Analysis, Funding
Analysis | Funding Top 10 Venture Round Investors in Cancer Therapeutics Celgene’s recent acquisition offer by Bristol-Myers Squibb has raised attention to its prolific dealmaking history. We covered this in a recent article in Endpoints News. Celgene was also...
by DealForma Analysts | Sep 4, 2018 | Analysis, Partnership Deals
Analysis | Partnership Deals Top 10 Biopharma Dealmakers by Upfront Cash Data from the DealForma database and an analysis were prepared for a story published in Endpoints News looking at top dealmakers in recent biopharma partnerships. We applied certain criteria to...
